Pier Capital’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Pier Capital’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-217,885	Closed	-$5.91M	–	132
2018 Q1	$5.91M	Buy	217,885 +57,762	+36%	+$1.73M	1.01%	50
2017 Q4	$4.61M	Buy	160,123 +43,408	+37%	+$1.19M	0.79%	85
2017 Q3	$2.83M	Buy	116,715 +63,289	+118%	+$1.5M	0.49%	96
2017 Q2	$1.19M	Buy	+53,426	New	+$1.12M	0.21%	105

Other funds holding DOVA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Pier Capital's DOVA Position: Q2 2018 in Review

Pier Capital sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q2 2018, closing a stake of 217,885 shares — an estimated $5.91M sold.

Pier Capital first reported a position in DOVA in Q2 2017 and held it in 4 quarters. The position peaked at $5.91M in Q1 2018. 60 funds tracked by Wall St. Rank hold DOVA as of Q2 2018.

Pier Capital reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Pier Capital sold 217,885 Dova Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $5.91M.
Pier Capital first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
Pier Capital's Dova Pharmaceuticals, Inc. Common Stock position peaked at $5.91M in Q1 2018.
60 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on Pier Capital's 13F filing for Q2 2018, filed 8 Aug 2018.